Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain training app shows promise for mild cognitive impairment

NCT ID NCT06264557

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a cognitive training software called SUPERBRAIN DEX in 140 people aged 50–85 with mild cognitive impairment (MCI), a condition that can lead to dementia. Participants used the software for 15–30 minutes daily, while a control group received an educational booklet on dementia prevention. The goal was to see if the software could improve memory and thinking better than simple education. The trial is now complete, and results will show whether this digital approach can help slow cognitive decline.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SUPERBRAIN DEX cognitive training software
What this could lead to
If it works, this software could offer a safe, drug-free way to help people with mild cognitive impairment maintain or improve their memory and thinking skills.
What could go wrong
This is a small, completed trial with 140 participants. The results may not apply to everyone, and the improvement might be modest. There is no guarantee the software will outperform simple education.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

140 people

The number who actually took part.

Started

Jan 2024

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 50 - 85years old 2. Those who meet all of the National Institute on Aging-Alzheimer's Association (NIA-AA) key clinical criteria below that may suspect mild cognitive impairment caused by Alzheimer's disease as of the screening date * Concern of the subject or guardian about the deterioration of cognitive function compared to before * More than one cognitive impairment * Maintaining the independence of overall daily life functions * It's not dementia 3. In at least one of the following neuropsychological tests conducted within one year of the screening date, the delayed recall score in the memory area was 'average -1' according to the standard score table corrected for education level and age. * Seoul Neuropsychological Screening Battery 2nd edition (SNSB-II) * Korean version of Consortium to Establish a Registry for Alzheimer's Disease (CERAD-K) * Literacy Independent Cognitive Assessment (LICA) 4. A person whose Korea-Mini Mental State Examination-2 (K-MMSE-2) score corresponds to "Average-1.5 standard deviation or higher" according to the standard score table corrected for education level and age as of the screening date 5. Those with a Global Clinical Dementia Rating (CDR) score of 0.5 and a memory item score of 0.5 or 1 as of the screening date 6. A person who has a guardian in regular contact with the subject * Defined to be able to support subjects during the clinical trial (compliance supervision and subject status reporting) and spend at least 8 hours per week with subjects 7. A person who is taking drugs (donepezil, galantamine, ribastigmine, memantine) for the purpose of improving cognitive function is taking drugs stably for at least 12 weeks as of the screening date 8. Those who have no difficulty using tablet PCs 9. A person who voluntarily decides to participate in this clinical trial and agrees to the subject's explanation and consent in writing 10. Those who are willing to comply with the clinical trial plan Exclusion Criteria: 1. Those diagnosed with dementia (including Alzheimer's disease, vascular dementia, infections of the central nervous system (e.g., Human Immunodeficiency Virus (HIV), syphilis, etc.), Creutzfeld-Jacob disease (Creutzfeld-Jacob disease), Pick disease, Huntington's disease, Parkinson's disease, etc.) as of the screening date 2. Those who have a history of diagnosing significant neurological diseases affecting cognitive function within one year of the screening date (e.g., stroke, multiple sclerosis, severe head trauma with loss of consciousness, normal cerebral hydrocephalus, epilepsy, brain tumors, cerebral infarction, spinal cord infarction or central nervous system infection) 3. Based on the screening date, major depressive disorder, bipolar disorder, schizophrenia, A person diagnosed with a serious mental illness such as drug addiction and alcoholism 4. Laboratory and/or vital signs tests as of the date of screening, any of the following * Those diagnosed with infectious or metabolic diseases that may cause cognitive decline in the subject (e.g., hypothyroidism, vitamin B12 deficiency, folate deficiency, neurotoxin, HIV) * Those with liver dysfunction (AST, ALT ≥ 3x upper limit of normal range) and/or renal dysfunction (serum creatinine ≥ 2x upper limit of normal range) * Those with uncontrolled hypertension (SBP \> 180 mmHg) and/or diabetes (HbA1c \> 11%) 5. Those who have severe or unstable cardiovascular disease (e.g., myocardial infarction, unstable angina, class III or IV heart failure by classification of the New York Heart Association (NYHA) within 24 weeks of the screening date) 6. Where the tester determines that he/she has a medical condition that may interfere with the completion of the clinical trial due to a serious or unstable physical condition (e.g., a history of malignant tumors within five years of the screening date (e.g., basal cell cancer and squamous cell carcinoma of the skin considered to have been completely resected and cured, cervical intraepithelial carcinoma, non-transparent prostate cancer, acute and severe asthma, active peptic ulcers, etc.) 7. If you can't walk, A person who can move using walking aids (e.g. walkers, canes, wheelchairs, etc.) 8. an illiterate patient who is unschooled (defined as unadmitted to a regular school) 9. Where the tester determines that a person does not have sufficient vision, hearing, language skills, motor skills, and comprehension to follow the examination procedures related to clinical trials 10. a person who is pregnant or nursing 11. For women of childbearing age, who do not agree with the medically permitted contraceptive method during the clinical trial * Hormonal contraception, intrauterine device (IUD) or intrauterine system (IUS), oviduct ligation, double blocking (male condom, female condom, cervical cap, a combination of contraceptive septum, contraceptive sponge-like blocking methods), a single blocking method with a combination of an alveolar agent 12. Those who are currently participating in other clinical trials or who have participated in other clinical trials within 90 days of screening 13. Other, ethical or clinical trial outcomes may be impacted and deemed inappropriate by the tester

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MCI are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ajou University Hospital

    Suwon, South Korea

  • Chonnam National University Hospital

    Kwangju, South Korea

  • Ewha Womans University Seoul Hospital

    Seoul, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Hanyang University Guri Hospital

    Guri-si, Gyeonggi-do, 11923, South Korea

  • Hanyang University Seoul Hospital

    Seoul, South Korea

  • Inha University Hospital

    Incheon, 22332, South Korea

  • Inje University Haeundae Paik Hospital

    Busan, South Korea

  • Koera University Guro Hospital

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea

  • The Catholic University of Korea, St. Vincent's Hospital

    Suwon, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.